Dare Bioscience shares are trading higher after the company announced the publication of its findings from the Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%.
Portfolio Pulse from Benzinga Newsdesk
Dare Bioscience shares are trading higher following the publication of findings from its Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%.
August 13, 2024 | 12:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dare Bioscience shares are trading higher after the company announced positive findings from its Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%.
The positive findings from the Phase 2b clinical study are likely to boost investor confidence in Dare Bioscience's product pipeline, leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100